Drug Profile
Dexifosfamide
Alternative Names: D 4809Latest Information Update: 06 Oct 1997
Price :
$50
*
At a glance
- Originator Celltech Group; Martinex R&D
- Developer Martinex R&D
- Class Antineoplastics
- Mechanism of Action DNA inhibitors; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Oct 1997 Discontinued-I for Cancer in Canada (Unknown route)
- 22 Feb 1996 Phase-I clinical trials for Cancer in Canada (Unknown route)
- 30 Nov 1995 D 4809 is now called dexifosfamide